Active ingredients: ramucirumab
What it is used for
CYRAMZA , in combination with paclitaxel, is indicated for the treatment of adult patients with advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluropyrimidine chemotherapy. CYRAMZA, as monotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy when treatment in combination with paclitaxel is not appropriate.
How to take it
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
- The way to take this medicine: Intravenous Infusion
- Store at 2 to 8 degrees Celsius
- Do not Freeze
- Do not Shake
- Protect from Light
- Lifetime is 24 Months.
Always read the label. If symptoms persist see your healthcare professional.
clear to slightly opalescent and colourless to slightly yellow solution without visible particles
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient ramucirumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf)